
How the hallmarks of aging organize research, why the list changed, and how to judge evidence behind claims about aging and human health.

The hallmarks of aging are proposed categories of biological processes that researchers use to organize evidence about age-related changes and the loss of healthy function.
The hallmarks are not a single biological pathway with an established sequence of steps in humans. A useful breakdown comes instead from the framework’s proposed hierarchy. An overview of that hierarchy describes primary, antagonistic and integrative hallmarks as different parts of an account of aging.
These steps explain the logic of the hierarchy. They should not be read as a timetable in which everyone passes through a fixed succession of hallmark stages.
The authors of the 2023 Cell review explicitly described the hallmarks as interconnected. The categories therefore work better as related research questions than as separate boxes.
That changes how a study should be read. A result assigned to one hallmark still needs to be considered alongside the other processes examined in the experiment. The category tells readers where the researchers placed their question; it does not replace the experiment’s methods or results.
For the same reason, a claim about “targeting a hallmark” needs more detail. Which process was altered? What else was measured? Those questions are more informative than the label alone.
The clearest common ground is the framework’s organizing role in aging research. The 2023 Cell review presented interconnected categories and proposed criteria for evaluating them. It supplied a vocabulary for discussing age-related biology, while the published debate concerns how strongly particular claims of hallmark status are justified.
The framework began with nine proposed hallmarks in a 2013 Cell review. In 2023, the same five authors expanded it to twelve in Hallmarks of aging: An expanding universe. The additions were disabled macroautophagy, chronic inflammation and dysbiosis.
The twelve categories are:
The revision matters because it shows that the original authors changed their framework. The list was a scientific proposal that could be updated, not an immutable classification.
The authors also proposed three tests for hallmark status. A process should manifest with age. Experimentally accentuating it should accelerate aging. Intervening on it should offer an opportunity to decelerate, stop or reverse aging.
Those are proposed criteria, not three interchangeable kinds of evidence. Observing a change addresses a different question from deliberately worsening it. An intervention experiment asks another question again: whether changing the process improves an aging outcome.
For readers, this distinction provides a practical way to sort claims before considering their implications. First identify which test a study addresses. Then examine what the researchers actually measured.
A 2026 EMBO Journal article, Seven ways not to think carefully about aging, argued that the criteria used to assign hallmark status are heterogeneous and problematic. It cautioned that a process changing with age does not by itself establish that it causes normal aging. Nor does early death after experimental disruption settle that question.
The distinction concerns what an experiment establishes. Showing that a process matters for survival is not automatically the same as showing how it contributes to ordinary aging. The critique challenges the interpretation of evidence rather than proving that every hallmark is unsupported.
A useful reading question follows: did the experiment examine normal aging or the consequences of disrupting a biological process? The answer helps define the conclusion the study can support.
The same EMBO Journal critique cautioned against treating cell-culture or invertebrate findings as equivalent to evidence from mammalian aging research. The framework itself also does not establish that every category has equally strong causal evidence or equally strong evidence in humans.
The practical response is to identify the experimental model before interpreting the result. A claim about aging should retain the identity of the system studied rather than becoming a general statement about people.
Next, check the outcome. An age-related association, an experimentally worsened process and an improved aging outcome answer different questions. Keeping model and outcome together is more informative than assigning a finding a general label such as “longevity evidence.”
The framework’s expansion shows that its boundaries have already changed. The available reviews do not establish that the twelve categories provide a complete explanation of aging. Nor does discussion of an additional candidate establish that it has joined the original framework or gained broad acceptance.
Future proposals therefore need more than a new label. Readers can ask how the proposed category relates to existing ones and what evidence supports treating it separately. A useful revision should make the research questions clearer rather than simply lengthen the list.
Treat a hallmark as a research category or hypothesis. The twelve-item review did not establish a particular consumer test or treatment. Its categories are not diagnoses, personal biological-age scores or proof that a targeted intervention will extend human life.
Start with the study’s question. Identify whether it reports an association, an experimental disruption or an intervention outcome. Then check the model and the measured result before accepting a broader claim.
When a claim introduces a biological-age number, ask what that measurement represents. AgeAmaze’s discussion of the different questions aging measurements address offers related context. For claims about personal testing, consider the separate issue of whether a result has a clear clinical interpretation.
The hallmarks earn their place by helping researchers frame better questions. Keep the map useful by asking what each experiment actually tested.
Judging a hallmark study for human relevance starts with identifying what was tested; AgeAmaze explains the evidence behind that judgment. For research-minded adults facing animal findings presented as human benefits, its coverage clarifies study types and uncertainty without turning early results into treatment promises.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog